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Available online 9 October 2018Background: Despite growing waiting lists for renal transplants, hesitations persist with regard to the use of de-
ceased after cardiac death (DCD) renal grafts. We evaluated the outcomes of DCD donations in The Netherlands,
the country with the highest proportion of DCD procedures (42.9%) to test whether these hesitations are justi-
ﬁed.
Methods: This study included all procedureswith grafts donated after brain death (DBD) (n= 3611) and cardiac
death (n=2711) performedbetween 2000 and 2017. Transplant outcomeswere comparedby KaplanMeier and
Cox regression analysis, and factors associatedwith short (within 90 days of transplantation) and long-termgraft
loss evaluated in multi-variable analyses.
Findings:Despite higher incidences of early graft loss (+50%) and delayed graft function (+250%) in DCD grafts,
10-year graft and recipient survival were similar for the two graft types (Combined 10-year graft survival: 73.9%
(95% CI: 72.5–75.2), combined recipient survival: 64.5% (95 CI: 63.0–66.0%)). Long-term outcome equivalence
was explained by a reduced impact of delayed graft function on DCD graft survival (RR: 0.69 (95% CI:
0.55–0.87), p b 0.001). Mid and long-term graft function (eGFR), and the impact of incident delayed graft func-
tion on eGFR were similar for DBD and DCD grafts.
Interpretation:Mid and long term outcomes for DCD grafts are equivalent to DBD kidneys. Poorer short term out-
comes are offset by a lesser impact of delayed graft function on DCD graft survival. This nation-wide evaluation
does not justify the reluctance to use of DCD renal grafts. A strong focus on short-term outcome neglects the su-
perior recovery potential of DCD grafts..2018.10.003.
R, Leiden Unive
.
en access articl© 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Research in context
Evidence before this study
While some studies suggest good outcomes for kidney grafts
donated after cardiac death (DCD), liberal use of these grafts is
still considered controversial. The Netherlands has a longstanding
tradition with DCD kidney grafts, and currently DCD procedures
account for 50% of all deceased donor procedures. Using national
transplantation registry data we compared the short and long
term outcomes for kidney grafts donated after brain and cardiac
death of all transplants performed between 2000 and 2017.
Added value of this study
Although this study conﬁrms a higher incidence of short term
graft loss and delayed graft function in DCD grafts. It shows equiv-
alent 10-year graft survival and recipient survival.
Implications of all the available evidence
This study shows similar long-term outcomes for grafts do-
nated after brain and cardiac death. Poorer short-term outcomes
for DCD grafts do not translate in worse long-term outcomes. Re-
sults dismiss a reticent attitude towards DCD grafts in an era of
pressing donor shortages.
26 A. Schaapherder et al. / EClinicalMedicine 4–5 (2018) 25–311. Introduction
Kidney transplantation profoundly improves quality of life and
longevity of end-stage renal disease patients and remains the only
curative option for patients with end-stage renal disease [1]. In an
era of growing waiting lists for renal transplants, and unacceptably
high waiting list-associated mortality, pressing donor shortages
have led to an increased use of so called “extended criteria grafts”
and kidney grafts obtained from donors deceased following cardiac
death (DCD) [2]. Transplantation procedures with DCD grafts are as-
sociated with increased incidences of primary non-function/early
graft loss and delayed graft function. The latter phenomenon is con-
sidered to negatively inﬂuence graft function and long-term graft
survival [3–6]. As a result, the use of DCD grafts remains controver-
sial [7], with many countries refraining from using these grafts
[8–11].
Remarkably, some small cohort studies [12–16], and follow up data
from the UK transplant registry do not support these reservations to-
wards the use of DCD grafts [17]. In fact, the UK registry data indicate
equal 5-year kidney graft survival rates for DCD grafts and grafts from
donors donated after brain-death (DBD). However, the low proportion
DCD grafts and concern with regard to differences in graft risk proﬁles;
in particular the reported increased susceptibility of DCD grafts for
(prolonged) cold-ischemia [17], raises questions on the generalizability
of the UK registry data.
In the light of the emerging discussion regarding a more liberal use
of DCD grafts, we considered an independent and adequately powered
evaluation of outcomes of DCD renal graft procedures relevant. This
analysis focuses on The Netherlands, which has a long and relative lib-
eral tradition with regard to the use of DCD grafts [18]. In fact, an eval-
uation for 2013 showed that the Netherlands is the country with the
highest proportion of DCDprocedures [19]. In fact, DCD procedures cur-
rently account for 50% of all deceased donor procedures performed
nationwide.This national registry-based study evaluates the outcomes of all




The Netherlands Organ Transplant Registry (NOTR) is a mandatory
nationwide registry of kidney transplant recipients fromall eight kidney
transplant centres in the Netherlands. The NOTR registry is managed by
the Dutch Transplant Foundation and includes recipient and donor
characteristics, and a variety of outcome parameters (Table 1). In the
ﬁrst year after transplantation, registry follow-up is atmonth 3, thereaf-
ter on a yearly basis. Quality checks are performed by on-site polls, busi-
ness rules in application and cross checks with the national dialysis
registry. We retrieved data on recipient and donor characteristics, and
transplantation outcomes for all procedures performed between Janu-
ary 1st 2000 and January 1st 2017. There were no missings for type of
donor, graft survival or recipient survival. With respect to follow-up
time for graft survival, 2.5% was missing and for recipient survival no
missing for follow-up time. Missing percentages were higher for some
of the clinical parameters. If appropriate the percentage missings for
these parameters are indicated in Table 1.
Grafts were preserved via arterial cold perfusion, generally using
University of Wisconsin (UW) or Histidine-tryptophan-ketoglutarate
(HTK) preservation solution. Almost all organs were retrieved and pre-
served bymeans of static cold storage. However, as of 2016most kidney
grafts were preserved using hypothermic machine perfusion. Organs
were allocated according to the Eurotransplant guidelines.
DCD kidneys were all from controlled circulatory death donors
(Maastricht category 3 (controlled DCD: awaiting cardiac arrest after
withdrawal of life-supporting treatments in the ICU) [20]. We excluded
grafts from uncontrolled circulatory death donors (n= 136), as well as
graft recipients younger than 12 years of age (n = 118), and combined
organ recipients (n = 366). This resulted in 3611 DBD and 2711 DCD
grafts available for ﬁnal analysis.
Theﬁrstwarm ischemic period in theDCDdonorswas deﬁned as the
time between cardiac arrest and start of cold perfusion. The time after
withdrawal of support with RR ≪ 50 mm Hg to cardiac arrest is not
available. Cold ischemia time was deﬁned as time from the start of
cold perfusion in the donor to start of the actual implantation in the re-
cipient. The anastomosis time was deﬁned as the time from organ re-
moval from cold storage to graft reperfusion in the recipient. Delayed
graft function was deﬁned by the need of dialysis because of initial
non-function in the ﬁrst week(s) after kidney transplantation that was
followed by functional recovery. Early graft loss was deﬁned as graft
loss within 90 days of transplantation.
2.2. Study End Points
Post transplantation outcomewas classiﬁed in the following catego-
ries: primary function, early graft loss (within 90 days of transplanta-
tion) or late graft loss (N90 days of transplantation). The kidney donor
risk index (KDRI) was calculated using the coefﬁcients provided [18]
and eGFR estimated by the Modiﬁcation of Diet in Renal Disease
(MDRD) formula. Patients who experienced graft failure, but did not
die during follow-up were censored at the end of follow-up. For these
analyses of -recipient overall survival-, only death was an event in the
analyses.
2.3. Data Statement
This study is based on datamade available by theNetherlands Organ
Transplant Registry (NOTR). Access to the data set is handled by the reg-
istry (info@transplantatiestichting.nl).
Table 1
Donor and recipient characteristicsa,b.
DBD DCD
N = 3611 (57.1%) N = 2711 (42.9%)
Sex donor (male) 1934 (47.6%) 1682 (58.4%)
Age donor (yr) 49.8 ± 15.2 49.4 ± 15.1
Body-mass index donor 25.2 ± 4.3 25.3 ± 4.6
Last creatinine donor (μmol/l) 77.4 ± 33.1 70.4 ± 26.0
eGFR (MDRD) donor (ml/min) 90.0 ± 37.6 101.5 ± 39.2
Cause of death donor (%)
Trauma 751 (20.8) 832 (30.7)
Stroke 2153 (59.6) 1060 (39.1)
Cardiac arrest 161 (4.5) 470 (17.3)
Other 546 (15.1) 349 (12.9)
Hypertension donor (%)
No 2210 (61.2) 2040 (75.2)
Yes 946 (26.2) 529 (19.5)
Unknown 455 (12.6) 142 (5.2)
Smoking donor (%)
No 1625 (45.0) 1282 (47.3)
Yes 1675 (46.4) 1271 (46.9)
Unknown 311 (8.6) 158 (5.8)
Cold ischemia time (hrs) 17.0 [13.2–22.0] 16.1 [12.8–20.1]
Cold ischemia time
distribution (%)
b 12 h 633 (17.5) 485 (17.9)
12–18 h 1266 (35.1) 1091 (40.2)
18–24 h 969 (26.8) 707 (26.1)
N 24 h 524 (14.5) 249 (9.2)
Unknown 219 (6.1) 179 (6.6)
Machine perfused 158 155
Graft anastomosis time (min) 33 [26–41] 32 [26–40]
KDRI 1.29 [1.04–1.62] 1.38 [1.12–1.71]
Sex recipient (male) 2083 (57.7%) 1692 (62.4%)
Age recipient (years) 51.9 ± 14.6 53.7 ± 13.3
BMI recipient (kg/m2) 25.3 ± 4.4 25.9 ± 4.4
No of previous transplants (%)
0 2705 (81.4) 2216 (87.1)
1 479 (14.4) 260 (10.7)
2 111 (3.3) 43 (1.8)
3 22 (0.7) 8 (0.3)
4 6 (0.2) 2 (0.1)
Mismatches (%)
HLA-Dr 0 1509 (41.9) 869 (32.3)
1 1815 (5.4) 1612 (59.9)
2 276 (7.7) 209 (7.8)
HLA-A 0 1409 (39.1) 815 (30.2)
1 2005 (49.5) 1583 (55.2)
2 587 (14.5) 425 (14.8)
HLA-B 0 955 (26.5) 445 (16.5)
1 1810 (50.3) 1616 (59.8)
2 836 (23.2) 642 (23.8)
Panel reactive antibodies N 5% (%) 570 (15.8) 252 (9.3)
Induction therapy
Anti-IL2r 1542 (42.7) 1239 (45.6)
ATG 119 (3.3) 81 (3.0)
Initial immune suppression
Ciclosporin A 964 (26.7) 539 (19.9)
Tacrolimus 2705 (71.0) 2245 (78.5)
Sirolimus 193 (5.4) 108 (4.0)
Mycophenolate 3317 (91.9) 2537 (93.6)
Corticosteroids 3513 (97.3) 2641 (97.4)
a Plus-minus values are means ± SD. Values between square brackets represent me-
dian and [interquartile range].
b Starting 2016 all grafts were machine perfused.
27A. Schaapherder et al. / EClinicalMedicine 4–5 (2018) 25–312.4. Statistical Analyses
Differences in donor, recipient, transplantation procedure-related
factors, and graft function between DBD and DCD donors were assessed
using Fischer exact tests, unpaired t-tests or Mann–Whitney rank tests
for categorical, normally-distributed and non-parametric data, respec-
tively. The continuous variables thatwere entered in the logistic regres-
sionmodels were visually inspected for skewness. For the KaplanMeiercurves, the proportional hazard assumption was tested on the basis of
Schoenfeld residuals after ﬁtting the model and there was no evidence
that the assumptionwas violatedwith a p-value of 0.88 for the graft sur-
vival and p = 0.28 for the recipient survival.
Kaplan Meier survival curves were generated for DBD versus DCD,
and in combination with or without delayed graft function. Graft sur-
vival time was deﬁned from date of transplantation to date of graft fail-
ure. Survival time was truncated at 10 years. Differences in graft and
recipient survival were studied by Cox Proportional Hazard analyses.
For the logistic regression analyses, variables were selected based on
clinical relevance (a priori) based on previous pilot research in a hospi-
tal based dataset. All factorswere studied in univariable analyses; there-
after, variables with a p-value of p b 0.1 were entered in the
multivariable analyses. For the graft and recipient survival, two multi-
variable models were built: one adjusting for age and sex and a second
full model including all baseline variables which were either different
between the donor types or deemed clinically relevant.
Missing data were entered in the model as a category unknown and
results are represented in the tables in case for categorical factors. In the
continuous factors, missing values were excluded for analyses. There
were no missings for the primary parameters (type of donor, graft sur-
vival or recipient survival).With respect to follow-up time for graft sur-
vival, 2.5%wasmissing and for recipient survival nomissings for follow-
up time. Missing information on secondary parameters is provided in
Table 1.
Results are represented as Hazard Ratio (HR) for the survival analy-
sis or OddsRatio (OR) for the logistic regressionwith corresponding95%
Conﬁdence Intervals (CI). Analyses were performed using STATA/SE
version 12.0 (StataCorp, Texas, USA) and SPSS 22.0 (IBM, Amsterdam,
The Netherlands).
3. Results
The NOTR registry, for the 2000–2017 interval, includes data for
3611 DBD (57.1%) and 2711 DCD (42.9%) kidney transplantations. The
17-year interval is associated with changes in medical treatment and
decisionmaking such as progressive use of older donors and DCD grafts,
and changes in immune suppression therapy (e.g. induction therapy)
which may positively and negatively affect transplant outcomes. This
aspect is included as “calendar months since transplantation” in the
multivariable analysis for early graft loss and DGF. Aspects included in
this factor and their correlation with the number of months-passed
since transplantation procedure are summarized in Supplemental
Table 1.
DBD and DCD donors differed with regard to sex-distribution, eGFR,
hypertension and smoking histories, and cause-of-death (Table 1). DCD
donors had superior pre-donation creatinine clearance, a lower preva-
lence of hypertension, but immunological matching was less optimal
than for DBD grafts (Table 1). Simple univariate correlations between
the various factors and outcomes are provided in Supplemental
Table 2. The slightly superior characteristics of DCD donors are reﬂected
in their modest lower median KDRI's after exclusion of the DCD compo-
nent from the equation (i.e.: 1.29 for the DCD group and 1.39 for the
DBD group (p b 1.10−25)). Cold ischemia and anastomosis times were
marginally shorter in the DCD donor group (Table 1).
The registry data indicate a 50% higher incidence of early graft loss,
and an almost 150% higher incidence of delayed graft function in DCD
grafts (Table 2). Multivariable analysis showed that only donor and
procedure-related factors associated with early graft loss (Supplemen-
tal Table 1), whereas incident delayed graft function associated with
donor, procedure and recipient-related factors (Supplemental
Table 2). Donor and recipient female sex associated with reduced inci-
dences of delayed graft function. The progressive association between
the transplant date (calendar months since transplantation), and early





Early graft loss (bday 90)
Primary non function 284 (7.9%) 279 (10.3%) b0.0001
Related to acute rejection 17 (0.5%) 12 (0.4%) 0.87
Delayed graft function
No 2409 (66.7%) 879 (32.4%) b0.0001
Yes 628 (17.4%) 1141 (42.1%)
Unknown 574 (15.9%) 691 (25.5%)
Late graft loss (Nday 90) 732 (20.3%) 533 (19.7%) b0.568
3 months eGFR [iqr]
−DGF 48.1 [37.8–60.9] 48.9 [37.1–58.8] b0.004
+DGF 39.6 [28.3–51.2] 38.9 [29.2–51.2] 0.13
Year 1 eGFR [iqr]
−DGF 49.5 [38.6–62.5] 49.4 [38.3–63.0] 0.61
+DGF 42.1 [30.9–54.8] 43.6 [31.4–54.9] 0.58
Year 5 eGFR [iqr]
−DGF 50.5 [37.6–66.1] 50.7 [36.5–64.4] 0.88
+DGF 44.8 [32.6–61.6] 43.0 [31.4–58.6] 0.15
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Fig. 1. A. Recipient death censored 10-year graft survival of DBD (blue) and DCD (red)
grafts transplanted in the Netherlands; HR (DBD reference): 1.07 (95% CI: 0.96–1.20); p
= 0.22. Schoenfeld residuals the proportional hazard assumption after ﬁtting the
model: p: 0.88. B. 10-year recipient survival for recipients of a DBD (blue) or DCD (red)
graft; HR (DBD reference): 1.03 (0.93–1.14); p = 0.56.
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tion in the DCD grafts did not impact long-term graft or recipient sur-
vival. In fact, 10-year graft survival (Fig. 1A and Table 3) and 10-year
recipient survival (Fig. 1B and Supplemental Table 3) were similar for
DBD and DCD grafts (Fig. 1A: HR for graft loss (DBD reference): 1.07
(95% CI: 0.96–1.20); p = 0.22; Fig. 2: adjusted-for-age-HR for recipient
death (DBD reference): 1.02 (95%CI: 0.92–1.12); p=0.73). Considering
the highly signiﬁcant differences in donor characteristics (Table 1), an
additional Cox proportional hazard analyses for the two survival out-
comes (graft survival (Table 3) and recipient survival (Supplemental
Table 3) was performed for two models; one model adjusting for age
and sex, and one full model. The model adjusted for age and sex indi-
cated an HR of respectively 1.12 (95% CI: 1.00–1.26; p = 0.05) and
0.98 (95% CI: 0.89–1.08; p=0.72) for graft survival (Table 3) and recip-
ient survival (Supplemental Table 3). HRs for the fully adjusted models
were: 1.08 (95% CI: 0.95–1.24; p = 0.24) for graft survival, and 1.03
(95% CI: 0.92–1.16; p = 0.55) for recipient survival.
In the light of expressed concerns with regard to a disproportionate
impact of longer ischemia times onDCDgrafts outcomes [17],we specif-
ically addressed the impact of prolonged (N24 h) cold ischemia time on
outcome. In fact, prolonged cold ischemia time disproportionally im-
pacted early graft survival (viz. graft loss within 90-days of transplanta-
tion) in the DCD group (early graft losses: 17.1 vs. 10.7% in the DCD and
DBD group respectively, P = 0.007). However, the similar conditional
graft survival for grafts surviving the ﬁrst 90 days (HR for graft loss
(DBD is reference) 1.15 (0.82–1.62); p=0.41) indicates that thedispro-
portionate effect reﬂects impaired graft recovery.
Comparable 10-year graft survival for DBD and DCD grafts in the
context of a more than doubled incidence of delayed graft function in
DCD grafts implies differential impacts of delayed graft function on
graft outcome in the two donor types. A discordant effect is supported
by the differential impacts of incident delayed graft function on graft
survival when censored for early graft loss (and recipient death)
(Fig. 2: HR for graft loss after delayed graft function 2.11 (95% CI:
1.73–2.57) for DBD grafts vs. 1.46 (95% CI: 1.22–1.75) for the DCD grafts,
P= 0.001) (graft survival for DBD and DCD grafts without delayed graft
function is reference)) and discordant associations between incident
delayed graft function and graft loss in DBD and DCD grafts (Supple-
mental Tables 4–7).
The impact of delayed graft function on graft function (estimated
clearance) on the other hand was similar for both donor types, with
equal 1- and 5-year eGFRs in DBD and DCD grafts without delayed
graft function, and approximately 12% lower eGFRs in grafts that
sustained delayed graft function (Table 2).4. Discussion
Results of this nation-wide evaluation of data from a society with an
almost equal allocation of DCD and DBD renal grafts show similar mid-
and long-term survival outcomes for DCD and DBD grafts.
Although someexperts call for amore liberal use of DCDdonor grafts
in the light of the high waiting list associated mortality (in fact, for the
US alone almost 5000 patients die annually while waiting for kidney
transplant) [21], high incidences of delayed graft function and early
graft loss in DCD grafts remain a major source of concern that prevents
a more liberal use of this type of grafts [8]. As result, the use of kidney
grafts donated after cardiac death as a highly signiﬁcant source of
donor organs remains a matter of great controversy [2]. In most socie-
ties including theUS, the number of DCDprocedures performed has sta-
bilized at approximately 10–20% of the total of deceased donor
procedures performed [22].
A less reticent attitude towards DCD grafts is supported by prelimi-
nary reports from small observational studies [12–16], and in particular
by data from the UK registry [17,19]. Although all reports indicate sim-
ilar outcomes for DCD and DBD grafts, small sized studies are sensitive
to publication bias [23], and small proportions of DCD procedures
(less than 10% of the procedures) raise concerns on a potential selection
Table 3
Cox proportional hazard analyses for Graft Failure.





Factor HR (95% CI) P-value HR (95% CI) p-value
Model 1: adjusted age and sex Model 2: fully adjusted
Donor type DBD Reference Reference
DCD 1.12 (1.00–1.26) 0.05 1.08 (0.95–1.24) 0.24
Sex donor Male Reference Reference
Female 1.00 (0.89–1.12) 0.97 1.01 (0.89–1.15) 0.85
Age donor Continuous 1.02 (1.02–1.03) b0.001 1.01 (1.00–1.01) b0.001
Sex recipient Male Reference Reference
Female 1.08 (0.96–1.21) 0.19 1.08 (0.96–1.23) 0.20
Age recipient Continuous 0.99 (0.98–0.99) b0.001 0.99 (0.98–0.99) b0.001
BMI donor Continuous 0.99 (0.98–1.01) 0.52
Creatinine donor Continuous 1.00 (0.99–1.00) 0.06
Cause of death donor Trauma Reference
Stroke 1.13 (0.95–1.34) 0.18
Cardiac arrest 0.96 (0.74–1.24) 0.77
Other 1.08 (0.85–1.35) 0.51
Hypertension donor No Reference
Yes 1.14 (0.98–1.33) 0.06
Unknown 1.11 (0.87–1.41) 0.38
Smoking donor No Reference
Yes 1.10 (0.97–1.25) 0.14
Unknown 0.94 (0.73–1.21) 0.66
Cold ischemia time Continuous 1.02 (1.02–1.03) b0.001
Graft anastomosis time Continuous 1.00 (1.00–1.01) 0.03
Early graft loss No Reference
Yes 154.7 (124–192) b0.001
BMI recipient Continuous 1.01 (0.99–1.03) 0.05
Mismatches HLA-Dr 0 Reference
1 1.20 (1.05–1.38) 0.007
2 1.24 (0.94–1.64) 0.12
Mismatches HLA-A 0 Reference
1 0.98 (0.85–1.13) 0.84
2 1.15 (0.94–1.42) 0.17
Mismatches HLA-B 0 Reference
1 0.85 (0.73–1.02) 0.09
2 0.99 (0.81–1.21) 0.95
Panel reactive antibodies Continuous 1.01 (1.00–1.01) b0.001
29A. Schaapherder et al. / EClinicalMedicine 4–5 (2018) 25–31bias with respect to superior donor characteristics of DCD grafts ac-
cepted for transplantation. This concern has been partially eliminated
by updated evaluation for the UK that incorporated the increased use
of DCD grafts in recent years [19], but follow up time still remains lim-
ited, and there is a considerable gap in recipient age between recipients
of DBD and DCD grafts pointing to cautiousness with respect to the use
of DCD grafts in younger patients. As result use of DCD grafts remains a
matter of on-going debate, and the reticent towards use of DCD grafts
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Fig. 2. Differential impacts of delayed graft function on recipient death censored graft
survival of DBD and DCD grafts (grafts with primary non function are excluded). HR for
graft loss after delayed graft function in DCD grafts (DBD reference): 0.69 (95% CI:
0.55–0.87); P = 0.001.authorities, that are currently discussing whether or not to adopt a
more liberal attitude to the use DCD donor grafts in kidney transplanta-
tion, we performed a nation-wide evaluation of outcomes after DCD do-
nation for the Netherlands.
With an almost equal share of DBD and DCD grafts, and comparable
donor and recipient characteristics, the situation in the Netherlands is
uniquely positioned to evaluate the outcomes for DBD and DCD proce-
dures. This setting not only allows for the evaluation of a large number
of DCD procedures, but it also limits selection biases that may result
from a preferential use of DCD graftswith superior donor characteristics
(i.e. young donor age; short ischemia time). The liberal attitude towards
DCD grafts in Dutch transplantation centres is reﬂected in the high pro-
portion of DCD grafts (41% for the 17 year observation period evaluated
in this study, 50% for the year 2016), and comparable donor character-
istics for DBD and DCD grafts. The Dutch policy with respect to use of
DCD (and extended criteria) grafts presumably explains the relatively
high incidence of early graft loss (overall incidence for the 2000–2017
interval in the Netherlands 6% vs. 2.8% for the UK [19]). Noticeably,
this did not impact overall outcomes with 10-year graft survival rates
for the Netherlands (73.9%) being similar to those reported for the UK
(74.4%) [19]) and slightly better to those of Caucasian American recipi-
ents 71% [24].
Although the cohort data for the Netherlands conﬁrm the higher in-
cidences of early graft loss and delayed graft function in DCD grafts,
long-term graft and recipient survival for DBD andDCDgraftswere sim-
ilar. We consider it unlikely that this equivalence relates to differences
in donor- or recipient characteristics as the observed differences were
minor, and as positive associations (e.g. higher percentage of male do-
nors in the DCD group) are balanced by negative factors (higher recipi-
ent age in the DCDgroup). Outcome equivalence despite an almost two-
30 A. Schaapherder et al. / EClinicalMedicine 4–5 (2018) 25–31and-a-half fold increase in the incidence of delayed graft function was
explained by differential impacts of delayed graft function on graft sur-
vival in DCD than DBD grafts. As such a focus on short-term outcomes
ignores the superior recovery characteristics of DCD grafts.
Dutch registry data conﬁrm a higher susceptibility of DCD grafts for
prolonged cold-ischemia as also reported for the UK-cohort [18]. Re-
markably, detailed exploration of this phenomenon showed that this
negative impact is limited to a higher risk for early graft loss: prolonged
cold ischemia times did not disproportionately impact early graft loss-
censored-graft-survival and rejection episodes. Implying the decisions
to accept these grafts should be primarily based on the consequences
of early graft loss to the recipient.
Long-term survival and functional equivalence, and comparable
rates of rejection-related graft losses for DCD and DBD grafts imply
that under the current immunosuppressive regimens immunological
aspects are not a main point of concern with regard to the use of DCD
grafts. The higher incidence of delayed graft function and more pro-
found impact of prolonged cold ischemia time on early DCD graft sur-
vival, and the pronounced negative effect of delayed graft function on
DBD-graft survival rather points to differences in graft resilience. In
this context, DCD grafts appear to sustain a more profound ischemic in-
sult, which is compensated by a superior functional recovery potential.
The latter is supported by the graft recovery analyses (eGFR) showing
equal function for DCD and DBD grafts during prolonged follow-up.
One could speculate that the differences in resilience relate to a negative
impact of donor brain death on DBD grafts [25,26], and/or activation of
tissue protective responses such as ischemic preconditioning [27], and
activation of the innate repair receptor [28] during the initial warm is-
chemia episode following cardiac death in DCD grafts. A further, and
non-exclusive explanation is that incident delayed graft function in
DBD grafts marks a poorer graft quality.
Multivariable analyses stressed the impact of the ﬁrst warm ische-
mic period on incident early graft loss and delayed graft function [29].
In fact, for incident delayed graft function the impact of 1 min of
warm ischemia equalled the impact of 1 h cold ischemia. As such at-
tempts to further minimize the ﬁrst warm ischemic period could im-
prove short term outcomes of DCD grafts. Longer anastomosis times
primarily associate with early graft loss. Yet, it cannot be excluded
that this association (partially) reﬂects technical difﬁculties during the
transplant procedure. The analysis did not indicate cold-ischemia time
as a negative factor for graft survival [17], this phenomenonmay reﬂect
the notion that the negative impact of cold ischemia times in mainly
limited to ischemia times over 24 h [17], and the progressive awareness
on avoiding long cold ischemia times in the Netherlands (Supplemental
Table 2). As result the number of grafts with cold ischemia times ex-
ceeding 24 h in the current study is low.
Irrespective of the donor type, multivariable analysis indicated
lower incident delayed graft function for grafts of female donors. Sex-
associated differences in graft survival were not observed for mid and
long term outcome (not shown). Conclusions from a recent experimen-
tal and data base study conﬁrm this observation, and suggest that supe-
rior short term outcomes in females relate to an estrogen-mediated
mechanism [30].
Observed beneﬁcial associations between donor height and short
termoutcomemay relate to amass-effectwith a higher number of func-
tional units in kidneys from taller donors [31].
Limitations: this is a registry based study. As such all limitations ac-
companying registry databases such asmissing data and registration er-
rors apply. The limited number of early graft losses interferes with a
more detailed evaluation of associated factors. Moreover, exploration
of potential associations is limited to the factors represented in the
data base, as such information on potentially relevant factors might be
missing. Although we adjusted for clinically relevant factors, this
might have led to residual confounding. Third, clinical practices and
guidelines may have changed over time. Although we introduced the
“calendar months since transplantation” as factor in the regressionanalysis for DGF and early graft loss, associations may have changed
over time.
In conclusion, this detailed report covering 17years' experiencewith
DCD procedures and that includes more than 2700 DCD procedures
shows that under the prevailing Dutch protocols mid- and long-term
outcomes after DBD and DCD kidney graft transplantation are similar.
These conclusions, and equal 10-year graft survival rates for TheNether-
land, UK and USA do not justify the reluctance to the use of DCD renal
grafts. A strong focus on short-term outcomes neglects the superior re-
covery potential of DCD grafts.
The increased incidences of early graft loss following longer ische-
mia times (over 24 h) call for stricter guidelines with respect to the lo-
gistics of DCD procedures.
Outstanding Questions
In the light of donor shortages, there needs to be more attention for
the apparent excellent recovery potential and adequate long-term sur-
vival of renal grafts donated after cardiac death. The reluctance to the
use of these grafts should be questioned.
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